Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.71 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.71 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.71 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL978831 | 1.00 | GLRA1 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25330917 | 0.97 | OR51E2 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL22518912 | 0.97 | GLRA1 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL16600 | 0.93 | GLRA1 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL6237269 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL27455875 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL7078758 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL6237177 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25331577 | 0.91 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL28013371 | 0.91 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279878-B | Cleaning composition | 联合利华知识产权控股有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-117899041-A | Astragaloside effervescent tablet and preparation process and application thereof | 浙江省肿瘤医院 | 2024-04-19 | — | — | CN | claimed |
| CN-115026299-A | Continuous flow macro preparation method of nano silver wire | 四川蜀汉智博科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-113456697-A | Method for preparing stable polydatin-containing extract and extract thereof | 洛阳惠中兽药有限公司 | 2021-10-01 | — | — | CN | claimed |
| CN-113142456-A | Lutein effervescent tablet for protecting eyes and relieving visual fatigue and preparation method thereof | 金寨县二根筷子农业发展有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-108175754-A | Paracetamol in paracetamol effervessentes tablets and preparation method thereof | 重庆希尔安药业有限公司 | 2018-06-19 | — | — | CN | claimed |
| WO-2009152144-A2 | ALL DAY RHINITIC CONDITION TREATMENT REGIMEN | CORNERSTONE THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20080311196-A1 | All Day Rhinitic Condition Treatment Regimen | CORNERSTONE BIOPHARMA, INC. | 2008-12-18 | — | — | US | claimed |
| US-RE39239-E1 | administering a time release dosage of a pharmaceutically active agent effective core surrounded by a coating of a swellable, erodable polymer; delivery of active agent at about the time of awakening | POLICHEM SA (CH) | 2006-08-15 | — | — | US | claimed |
| CN-1210021-C | Novel formulation for inhibiting ethylene response in plants, method for preparing same and method for using same | LYTONE ENTPR INC (CN) | 2005-07-13 | — | — | CN | claimed |
| CN-1433301-A | Novel formulation for inhibiting ethylene response in plants, method for preparing same and method for using same | LYTONE ENTPR INC (CN) | 2003-07-30 | — | — | CN | claimed |
| EP-0954292-B1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLICHEM SA (LU) | 2003-07-02 | — | — | EP | claimed |
| EP-0954292-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.p.A. (IT) | 1999-11-10 | — | — | EP | claimed |
| US-5788987-A | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATION | POLI INDUSTRIA CHIMICA SPA (IT) | 1998-08-04 | — | — | US | claimed |
| WO-1998032425-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.P.A. (US) | 1998-07-30 | — | — | WO | claimed |
| US-5681583-A | SUSTAINED RELEASE; THE DISINTEGRATING RATE OF FIRST LAYER IS FASTER THAN THE SECOND LAYER | APR APPLIED PHARMA RESEARCH SA (CH) | 1997-10-28 | — | — | US | claimed |
| EP-0659074-A1 | MULTILAYERED CONTROLLED-RELEASE ORAL SOLID PHARMACEUTICAL FORMS | APR APPLIED PHARMA RESEARCH S.A. (CH) | 1995-06-28 | — | — | EP | claimed |
| WO-1995001781-A1 | MULTILAYERED CONTROLLED-RELEASE ORAL SOLID PHARMACEUTICAL FORMS | APR APPLIED PHARMA RESEARCH SA (CH) | 1995-01-19 | — | — | WO | claimed |
| EP-0363569-A1 | Spontaneously water-dispersible composition particularly suitable for treating the skin | COMPAGNA ITALIANA SALI C.I.S. S.p.A. (IT) | 1990-04-18 | — | — | EP | claimed |
| CN-120018844-A | Inhibitors of MYC and uses thereof | 西北大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-106714783-B | Effervescent composition and method for preparing same | 驶帝生命科学印度私人有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-115697310-B | Coated pharmaceutical composition and method for preparing the same | 应用材料公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119055604-A | Comprises acetaminophen and pharmaceutical composition of ibuprofen | AFT制药有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-115677762-B | Benzenesulfonyl amino phosphonate derivative and preparation method and application thereof | 遵义医科大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-117899041-A | Astragaloside effervescent tablet and preparation process and application thereof | 浙江省肿瘤医院 | 2024-04-19 | — | — | CN | disclosed |
| CN-114176229-B | Expandable microcapsules | 王子宾 | 2024-03-26 | — | — | CN | disclosed |
| EP-3082791-B1 | GASTRO-RETENTIVE ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING BACLOFEN | ETHYPHARM SA (FR) | 2024-03-20 | — | — | EP | disclosed |
| CN-117561082-A | Method for treating major depressive disorder and refractory depression | IX生物制药有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-113767188-B | Reactor for coating particles in a stationary chamber with rotating paddles | 应用材料公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-116133654-A | Methods and compositions for treating fungal infections | 纽库利私人有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115026299-B | Continuous flow macro preparation method of nano silver wire | 四川蜀汉智博科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115026299-A | Continuous flow macro preparation method of nano silver wire | 四川蜀汉智博科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-111803442-B | Stabilizer for improving bioavailability of ammonium glycyrrhetate S liquid dosage form and application thereof | 广州一品红制药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3492466-B1 | ORAL SOLID PREPARATION AND USE THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2022-06-01 | — | — | EP | disclosed |
| US-11312694-B2 | Method for making propenamide compound | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-20220033368-A1 | METHOD FOR MAKING PROPENAMIDE COMPOUND | KING ABDULAZIZ UNIVERSITY (SA) | 2022-02-03 | — | — | US | disclosed |
| US-20220009896-A1 | METHOD OF TREATING COLORECTAL CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-13 | — | — | US | disclosed |
| US-11214556-B1 | Method of treating colorectal cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-04 | — | — | US | disclosed |
| US-11155528-B2 | Bis-propenamide compounds and methods of treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-26 | — | — | US | disclosed |
| CN-113456697-A | Method for preparing stable polydatin-containing extract and extract thereof | 洛阳惠中兽药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-113142456-A | Lutein effervescent tablet for protecting eyes and relieving visual fatigue and preparation method thereof | 金寨县二根筷子农业发展有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-107308125-B | Oral formulations and lipophilic salts of methylnaltrexone | 惠氏有限责任公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210122721-A1 | BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-04-29 | — | — | US | disclosed |
| US-10836736-B1 | Pharmaceutical composition with cytotoxic activity on colorectal cancer cells | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-17 | — | — | US | disclosed |
| CN-111803442-A | Stabilizer for improving bioavailability of ammonium glycyrrhetate S liquid dosage form and application thereof | 广州一品红制药有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111683684-A | Methods for treating cysteamine-sensitive disorders | 硫创治疗公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-110742864-A | Preparation method of modified traditional Chinese medicine extract powder | 陕西中医药大学附属医院 | 2020-02-04 | — | — | CN | disclosed |
| CN-110690516-A | Waste lead-acid storage battery recovery treatment process | 骆驼集团(安徽)再生资源有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3492466-A1 | ORAL SOLID PREPARATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-104853750-B | Pharmaceutical formulations of N- [5- [2- (3, 5-dimethoxyphenyl) ethyl ] -2H-pyrazol-3-yl ] -4- [ (3R, 5S) -3, 5-dimethylpiperazin-1-yl ] benzamide | 阿斯利康(瑞典)有限公司 | 2018-06-26 | — | — | CN | disclosed |
| CN-108175754-A | Paracetamol in paracetamol effervessentes tablets and preparation method thereof | 重庆希尔安药业有限公司 | 2018-06-19 | — | — | CN | disclosed |
| EP-2161021-B1 | MEDICINAL FILM PREPARATION WITH RAPIDLY DISSOLVING PROPERTY AND FLEXIBILITY | SATO PHARMA (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-9421232-B2 | Method of preparation of compositions comprising dehydrated micro-organisms | VIRBAC SA (FR) | 2016-08-23 | — | — | US | disclosed |
| US-20160120921-A1 | COMPOSITIONS COMPRISING DEHYDRATED MICRO-ORGANISMS, METHOD OF PREPARATION THEREOF, AND USES THEREOF | VIRBAC SA (FR) | 2016-05-05 | — | — | US | disclosed |
| US-9259448-B2 | Compositions comprising dehydrated micro-organisms, method for preparing same, and uses thereof | VIRBAC SA (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9125836-B2 | Film preparation with rapidly dissolving property and flexibility | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| CN-103608342-A | Modified release formulations of 4-methyl-3- [ [4- (3-pyridinyl) -2-pyrimidinyl ] amino ] -N- [5- (4-methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) phenyl ] benzamide using an organic acid as co-solvent | NOVARTIS AG | 2014-02-26 | — | — | CN | disclosed |
| CN-102292088-B | Policosanol nanoparticles | NANORX INC | 2014-01-29 | — | — | CN | disclosed |
| CN-102933207-A | Fast dissolving solid dosage form | IX BIOPHARMA PTE LTD | 2013-02-13 | — | — | CN | disclosed |
| CN-102599608-A | Functional effervescent tablet and preparation method thereof | Changshu huifeng food co ltd | 2012-07-25 | — | — | CN | disclosed |
| CN-102292088-A | Policosanol nanoparticles | — | 2011-12-21 | — | — | CN | disclosed |
| US-20110014278-A1 | Compositions Comprising Dehydrated Micro-Organisms, Method for Preparing Same, and Uses Thereof | VIRBAC SA (FR) | 2011-01-20 | — | — | US | disclosed |
| US-20100150986-A1 | FILM PREPARATION WITH RAPIDLY DISSOLVING PROPERTY AND FLEXIBILITY | SATO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2161021-A1 | MEDICINAL FILM PREPARATION WITH RAPIDLY DISSOLVING PROPERTY AND FLEXIBILITY | Sato Pharmaceutical Co. Ltd. (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-20100047184-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AN EFFERVESCENT ACID-BASE COUPLE | CHIESI FARMACEUTICI S.P.A. (IT) | 2010-02-25 | — | — | US | disclosed |
| WO-2009152144-A2 | ALL DAY RHINITIC CONDITION TREATMENT REGIMEN | CORNERSTONE THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080311196-A1 | All Day Rhinitic Condition Treatment Regimen | CORNERSTONE BIOPHARMA, INC. | 2008-12-18 | — | — | US | disclosed |
| US-RE39239-E1 | administering a time release dosage of a pharmaceutically active agent effective core surrounded by a coating of a swellable, erodable polymer; delivery of active agent at about the time of awakening | POLICHEM SA (CH) | 2006-08-15 | — | — | US | disclosed |
| CN-1210021-C | Novel formulation for inhibiting ethylene response in plants, method for preparing same and method for using same | LYTONE ENTPR INC (CN) | 2005-07-13 | — | — | CN | disclosed |
| CN-1539814-A | Microwave method for synthesizing carbonate of natrium glycine | 四川大学 | 2004-10-27 | — | — | CN | disclosed |
| CN-1433301-A | Novel formulation for inhibiting ethylene response in plants, method for preparing same and method for using same | LYTONE ENTPR INC (CN) | 2003-07-30 | — | — | CN | disclosed |
| EP-0954292-B1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLICHEM SA (LU) | 2003-07-02 | — | — | EP | disclosed |
| EP-0954292-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.p.A. (IT) | 1999-11-10 | — | — | EP | disclosed |
| US-5788987-A | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATION | POLI INDUSTRIA CHIMICA SPA (IT) | 1998-08-04 | — | — | US | disclosed |
| WO-1998032425-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.P.A. (US) | 1998-07-30 | — | — | WO | disclosed |
| US-5681583-A | SUSTAINED RELEASE; THE DISINTEGRATING RATE OF FIRST LAYER IS FASTER THAN THE SECOND LAYER | APR APPLIED PHARMA RESEARCH SA (CH) | 1997-10-28 | — | — | US | disclosed |
| US-5646131-A | Method for solubilizing drugs using cyclodextrins and carboxylic acids | THE ARAB COMPANY FOR DRUG INDUSTRIES AND MEDICAL APPLICANCES (ACDIMA) (JO) | 1997-07-08 | — | — | US | disclosed |
| EP-0659074-A1 | MULTILAYERED CONTROLLED-RELEASE ORAL SOLID PHARMACEUTICAL FORMS | APR APPLIED PHARMA RESEARCH S.A. (CH) | 1995-06-28 | — | — | EP | disclosed |
| WO-1995001781-A1 | MULTILAYERED CONTROLLED-RELEASE ORAL SOLID PHARMACEUTICAL FORMS | APR APPLIED PHARMA RESEARCH SA (CH) | 1995-01-19 | — | — | WO | disclosed |
| EP-0363569-A1 | Spontaneously water-dispersible composition particularly suitable for treating the skin | COMPAGNA ITALIANA SALI C.I.S. S.p.A. (IT) | 1990-04-18 | — | — | EP | disclosed |
| US-4032650-A | CALCIUM DIACETONE-2-KETOGULONATE | A.E.C. SOCIETE DE CHIMIE ORGANIQUE ET BIOLOGIQUE (FR) | 1977-06-28 | — | — | US | disclosed |
| US-4032650-A | CALCIUM DIACETONE-2-KETOGULONATE | A.E.C. SOCIETE DE CHIMIE ORGANIQUE ET BIOLOGIQUE (FR) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836736-B1 | Pharmaceutical composition with cytotoxic activity on colorectal cancer cells | APC, DCK, ABCB1 | GLRA1 2997/4885SLC6A9 3878/4885OR51E2 4233/4885 |
| US-20210122721-A1 | BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER | APC, CCNE1, CCNI | GLRA1 2442/4885SLC6A9 2749/4885OR51E2 2655/4885 |
| US-20220009896-A1 | METHOD OF TREATING COLORECTAL CANCER | APC, SLC10A2, FOLR1 | GLRA1 2269/4885SLC6A9 3349/4885OR51E2 3967/4885 |
| US-11312694-B2 | Method for making propenamide compound | APC, CYP2C19, PKD1 | GLRA1 2024/4885SLC6A9 1625/4885OR51E2 2286/4885 |
| US-20220033368-A1 | METHOD FOR MAKING PROPENAMIDE COMPOUND | APC, CYP2C19, PKD1 | GLRA1 2024/4885SLC6A9 1625/4885OR51E2 2286/4885 |
| US-11155528-B2 | Bis-propenamide compounds and methods of treating cancer | APC, CCNE1, CCNI | GLRA1 2442/4885SLC6A9 2749/4885OR51E2 2655/4885 |
| US-11214556-B1 | Method of treating colorectal cancer | APC, SLC10A2, FOLR1 | GLRA1 2269/4885SLC6A9 3349/4885OR51E2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.